Skip to main content
Premium Trial:

Request an Annual Quote

Orchid and Genetic Technologies Exchange Licenses

NEW YORK, May 30 -- Orchid BioSciences and Genetic Technologies have licensed each other's technologies, the companies said today.


Genetic Technologies, based in Melbourne, Australia, obtains exclusive licenses to Orchid's SNP panels for paternity and forensic DNA testing services, as well as to Orchid's Elucigene diagnostic kits, for the areas of Australia, New Zealand, and Southeast Asia. Moreover, it acquires a non-exclusive license to primer extension patents held by Orchid.


In return, Orchid will receive royalties from revenues that Genetic Technologies will generate using these technologies. Orchid, located in Princeton, NJ, also receives an option to license Genetic Technologies' non-coding patents for SNP analysis, as well as clearance for past business activities that may have been covered by these patents.


Both companies exchanged upfront signing fees.


For further information, see the company statement.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.